Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 4/20 | 0.31 |
| ▸ | CDK9 | P50750 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6228444 | 0.88 | TYK2 (0.37) | KDM4EHTTDGAT1SMPD3NPC1 | |
| SCHEMBL11951634 | 0.81 | KDM4E (0.38) | KDM4EHTTALDH1A1CDK2CDK9 | |
| SCHEMBL12913573 | 0.81 | GPR119 (0.37) | KDM4EHTTALDH1A1HPGDMAPK1 | |
| SCHEMBL20558034 | 0.79 | GPR119 (0.36) | KDM4EHTTDGAT1NPC1MAPT | |
| SCHEMBL20542201 | 0.79 | KDM4E (0.34) | KDM4EHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL32686016 | 0.77 | KDM4E (0.56) | KDM4EHTTSMPD3NPC1MAPT | |
| SCHEMBL30579310 | 0.77 | SMPD3 (0.35) | KDM4EHTTSMPD3NPC1MAPT | |
| SCHEMBL125976 | 0.76 | SMPD3 (0.50) | KDM4EHTTSMPD3NPC1MAPT | |
| SCHEMBL11951631 | 0.76 | AHR (0.40) | KDM4ENPC1MAPTRAB9AMAPK1 | |
| Hydrochloric Acid SCHEMBL6805756 | 0.74 | SMPD3 (0.48) | KDM4EHTTSMPD3NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| EP-3268000-B1 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2021-08-04 | — | — | EP | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-8067424-B2 | Selective inhibitors for cyclin-dependent kinases | EMORY UNIVERSITY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100261683-A1 | Selective Inhibitors for Cyclin-Dependent Kinases | EMORY UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | KDM4E 3337/4885HTT 3938/4885DGAT1 1343/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | KDM4E 3337/4885HTT 3938/4885DGAT1 1343/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | KDM4E 4116/4885HTT 4641/4885DGAT1 2784/4885 |
| US-20100261683-A1 | Selective Inhibitors for Cyclin-Dependent Kinases | CDK7, CCNK, CDK17 | KDM4E 864/4885HTT 2276/4885DGAT1 2185/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | KDM4E 3160/4885HTT 4831/4885DGAT1 1483/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | KDM4E 4005/4885HTT 4735/4885DGAT1 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.